Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML

We evaluated the risk status and survival outcomes of 125 elderly acute myeloid leukemia (AML) patients treated with decitabine in combination with low-dose cytarabine, aclarubicin, and G-CSF (D-CAG). The risk status was evaluated by determining the frequency of recurring gene mutations using next-g...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Ming, Zhu, Han, Sun, Qian, Zhu, Yu, Miao, Yi, Yang, Hui, Qiu, Hai-Rong, Li, Jian-Yong, Qian, Si-Xuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185116/
https://www.ncbi.nlm.nih.gov/pubmed/32238611
http://dx.doi.org/10.18632/aging.102973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185116/
https://www.ncbi.nlm.nih.gov/pubmed/32238611
http://dx.doi.org/10.18632/aging.102973

Ejemplares similares